HC Wainwright Has Bullish Estimate for Imunon Q3 Earnings

Imunon, Inc. (NASDAQ:IMNN) – Investment analysts at HC Wainwright boosted their Q3 2026 EPS estimates for shares of Imunon in a research report issued to clients and investors on Thursday, August 13th. HC Wainwright analyst E. Bodnar now anticipates that the company will post earnings of ($0.57) per share for the quarter, up from their prior forecast of ($0.84). The consensus estimate for Imunon’s current full-year earnings is ($2.63) per share. HC Wainwright also issued estimates for Imunon’s Q4 2026 earnings at ($0.24) EPS, FY2026 earnings at ($1.74) EPS, FY2027 earnings at ($1.06) EPS, FY2028 earnings at ($1.05) EPS, FY2029 earnings at ($0.73) EPS and FY2030 earnings at ($0.53) EPS.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Imunon in a report on Friday, July 17th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Imunon currently has a consensus rating of “Hold” and a consensus price target of $10.00.

Imunon Price Performance

NASDAQ IMNN opened at $1.58 on Monday. The firm’s fifty day simple moving average is $1.77 and its two-hundred day simple moving average is $2.49. The company has a current ratio of 1.82, a quick ratio of 1.82 and a debt-to-equity ratio of 2.86. Imunon has a 12-month low of $1.47 and a 12-month high of $6.96. The firm has a market capitalization of $8.87 million, a P/E ratio of -0.41 and a beta of 1.97.

Imunon (NASDAQ:IMNN) last posted its earnings results on Tuesday, August 11th. The company reported ($0.54) EPS for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.33.

Hedge Funds Weigh In On Imunon

A hedge fund recently bought a new position in Imunon stock. Armistice Capital LLC bought a new position in Imunon, Inc. (NASDAQ:IMNN) in the fourth quarter, according to its most recent filing with the SEC. The firm bought 266,886 shares of the company’s stock, valued at approximately $1,017,000. Armistice Capital LLC owned approximately 8.69% of Imunon as of its most recent SEC filing. Hedge funds and other institutional investors own 4.47% of the company’s stock.

Imunon Company Profile

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma.